Listed

TuHURA Biosciences, Inc.

HURANasdaqCIK 1498382HealthcareFiscal year ends Dec 31

Standardized line items from XBRL company facts, the last twelve quarters. Negative values are in parentheses. A figure marked d is derived from year-to-date figures.

Income statement

Revenue$0, Q1 FY2026
Net income−$9.2m, Q2 FY2026
TuHURA Biosciences, Inc., income statement, quarterly
Line itemUnitQ1 FY20232023-09-30Q2 FY20232023-12-31Q3 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Revenue$knot reportednot reported0.0Revenue, Q3 FY2024, three months to 2024-03-31$0. XBRL concept us-gaap:Revenues. 10-Q filed 2025-05-15, accession 0000950170-25-072745.Report this figure0.0Revenue, Q2 FY2024, three months to 2024-06-30$0. XBRL concept us-gaap:Revenues. 10-Q filed 2025-08-14, accession 0000950170-25-108972. Derived: 6-month figure less the 3-month figure.Report this figure0.0Revenue, Q3 FY2024, three months to 2024-09-30$0. XBRL concept us-gaap:Revenues. 10-Q filed 2025-11-14, accession 0001193125-25-281539. Derived: 9-month figure less the 6-month figure.Report this figure0.0Revenue, Q4 FY2024, three months to 2024-12-31$0. XBRL concept us-gaap:Revenues. 10-K filed 2026-03-31, accession 0001193125-26-134950. Derived: 12-month figure less the 9-month figure.Report this figure0.0Revenue, Q1 FY2025, three months to 2025-03-31$0. XBRL concept us-gaap:Revenues. 10-Q filed 2026-05-15, accession 0001193125-26-227245.Report this figure0.0Revenue, Q2 FY2025, three months to 2025-06-30$0. XBRL concept us-gaap:Revenues. 10-Q filed 2025-08-14, accession 0000950170-25-108972. Derived: 6-month figure less the 3-month figure.Report this figure0.0Revenue, Q3 FY2025, three months to 2025-09-30$0. XBRL concept us-gaap:Revenues. 10-Q filed 2025-11-14, accession 0001193125-25-281539. Derived: 9-month figure less the 6-month figure.Report this figure0.0Revenue, Q4 FY2025, three months to 2025-12-31$0. XBRL concept us-gaap:Revenues. 10-K filed 2026-03-31, accession 0001193125-26-134950. Derived: 12-month figure less the 9-month figure.Report this figure0.0Revenue, Q1 FY2026, three months to 2026-03-31$0. XBRL concept us-gaap:Revenues. 10-Q filed 2026-05-15, accession 0001193125-26-227245.Report this figurenot reported
Research and development$k1,859Research and development, Q1 FY2023, three months to 2023-09-30$1.9m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2024-11-14, accession 0000950170-24-127199.Report this figure111Research and development, Q2 FY2023, three months to 2023-12-31$111.0k. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2024-02-14, accession 0000950170-24-015204.Report this figure3,589Research and development, Q3 FY2024, three months to 2024-03-31$3.6m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-05-15, accession 0000950170-25-072745.Report this figure2,823Research and development, Q4 FY2024, three months to 2024-06-30$2.8m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-08-14, accession 0000950170-25-108972.Report this figure2,947Research and development, Q1 FY2024, three months to 2024-09-30$2.9m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-11-14, accession 0001193125-25-281539.Report this figure3,976Research and development, Q4 FY2024, three months to 2024-12-31$4.0m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2026-03-31, accession 0001193125-26-134950. Derived: 12-month figure less the 9-month figure.Report this figure4,582Research and development, Q1 FY2025, three months to 2025-03-31$4.6m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-05-15, accession 0001193125-26-227245.Report this figure4,927Research and development, Q2 FY2025, three months to 2025-06-30$4.9m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-08-14, accession 0001193125-26-350451.Report this figure4,969Research and development, Q3 FY2025, three months to 2025-09-30$5.0m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-11-14, accession 0001193125-25-281539.Report this figure6,055Research and development, Q4 FY2025, three months to 2025-12-31$6.1m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2026-03-31, accession 0001193125-26-134950. Derived: 12-month figure less the 9-month figure.Report this figure5,233Research and development, Q1 FY2026, three months to 2026-03-31$5.2m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-05-15, accession 0001193125-26-227245.Report this figure6,620Research and development, Q2 FY2026, three months to 2026-06-30$6.6m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-08-14, accession 0001193125-26-350451.Report this figure
Operating income$knot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reported
Interest expense$knot reportednot reported255Interest expense, Q3 FY2024, three months to 2024-03-31$255.1k. XBRL concept us-gaap:InterestExpense. 10-Q filed 2025-05-15, accession 0000950170-25-072745.Report this figure1,357Interest expense, Q4 FY2024, three months to 2024-06-30$1.4m. XBRL concept us-gaap:InterestExpense. 10-Q filed 2025-08-14, accession 0000950170-25-108972.Report this figure2,003Interest expense, Q1 FY2024, three months to 2024-09-30$2.0m. XBRL concept us-gaap:InterestExpense. 10-Q filed 2025-11-14, accession 0001193125-25-281539.Report this figure523Interest expense, Q4 FY2024, three months to 2024-12-31$522.8k. XBRL concept us-gaap:InterestExpense. 10-K filed 2026-03-31, accession 0001193125-26-134950. Derived: 12-month figure less the 9-month figure.Report this figurenot reportednot reported16.5Interest expense, Q3 FY2025, three months to 2025-09-30$16.5k. XBRL concept us-gaap:InterestExpense. 10-Q filed 2025-11-14, accession 0001193125-25-281539.Report this figure609Interest expense, Q4 FY2025, three months to 2025-12-31$608.8k. XBRL concept us-gaap:InterestExpense. 10-K filed 2026-03-31, accession 0001193125-26-134950. Derived: 12-month figure less the 9-month figure.Report this figure28.0Interest expense, Q1 FY2026, three months to 2026-03-31$28.0k. XBRL concept us-gaap:InterestExpense. 10-Q filed 2026-05-15, accession 0001193125-26-227245.Report this figure468Interest expense, Q2 FY2026, three months to 2026-06-30$467.6k. XBRL concept us-gaap:InterestExpense. 10-Q filed 2026-08-14, accession 0001193125-26-350451.Report this figure
Net income$k(2,962)Net income, Q1 FY2023, three months to 2023-09-30−$3.0m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2024-11-14, accession 0000950170-24-127199.Report this figure(1,023)Net income, Q2 FY2023, three months to 2023-12-31−$1.0m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2024-02-14, accession 0000950170-24-015204.Report this figure(4,842)Net income, Q3 FY2024, three months to 2024-03-31−$4.8m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-14, accession 0001193125-25-281539.Report this figure(5,265)Net income, Q4 FY2024, three months to 2024-06-30−$5.3m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-14, accession 0001193125-25-281539.Report this figure(5,579)Net income, Q1 FY2024, three months to 2024-09-30−$5.6m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-14, accession 0001193125-25-281539.Report this figure(5,996)Net income, Q4 FY2024, three months to 2024-12-31−$6.0m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-03-31, accession 0001193125-26-134950. Derived: 12-month figure less the 9-month figure.Report this figure(6,664)Net income, Q1 FY2025, three months to 2025-03-31−$6.7m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-14, accession 0001193125-26-350451.Report this figure(9,524)Net income, Q2 FY2025, three months to 2025-06-30−$9.5m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-14, accession 0001193125-26-350451.Report this figure(7,102)Net income, Q3 FY2025, three months to 2025-09-30−$7.1m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-14, accession 0001193125-25-281539.Report this figure(6,761)Net income, Q4 FY2025, three months to 2025-12-31−$6.8m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-03-31, accession 0001193125-26-134950. Derived: 12-month figure less the 9-month figure.Report this figure(7,537)Net income, Q1 FY2026, three months to 2026-03-31−$7.5m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-14, accession 0001193125-26-350451.Report this figure(9,223)Net income, Q2 FY2026, three months to 2026-06-30−$9.2m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-14, accession 0001193125-26-350451.Report this figure
Diluted EPS$ per sharenot reportednot reported(0.40)Diluted EPS, Q3 FY2024, three months to 2024-03-31−$0.40 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-05-15, accession 0000950170-25-072745.Report this figure(0.43)Diluted EPS, Q4 FY2024, three months to 2024-06-30−$0.43 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-08-14, accession 0000950170-25-108972.Report this figure(0.54)Diluted EPS, Q1 FY2024, three months to 2024-09-30−$0.54 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-14, accession 0001193125-25-281539.Report this figurenot reported(0.15)Diluted EPS, Q1 FY2025, three months to 2025-03-31−$0.15 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-15, accession 0001193125-26-227245.Report this figure(0.21)Diluted EPS, Q2 FY2025, three months to 2025-06-30−$0.21 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-14, accession 0001193125-26-350451.Report this figure(0.14)Diluted EPS, Q3 FY2025, three months to 2025-09-30−$0.14 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-14, accession 0001193125-25-281539.Report this figurenot reported(0.13)Diluted EPS, Q1 FY2026, three months to 2026-03-31−$0.13 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-15, accession 0001193125-26-227245.Report this figure(0.14)Diluted EPS, Q2 FY2026, three months to 2026-06-30−$0.14 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-14, accession 0001193125-26-350451.Report this figure
Basic EPS$ per share(63.92)Basic EPS, Q1 FY2023, three months to 2023-09-30−$63.92 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2024-11-14, accession 0000950170-24-127199.Report this figure(0.24)Basic EPS, Q2 FY2023, three months to 2023-12-31−$0.24 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2024-02-14, accession 0000950170-24-015204.Report this figure(0.40)Basic EPS, Q3 FY2024, three months to 2024-03-31−$0.40 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-05-15, accession 0000950170-25-072745.Report this figure(0.43)Basic EPS, Q4 FY2024, three months to 2024-06-30−$0.43 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-08-14, accession 0000950170-25-108972.Report this figure(0.54)Basic EPS, Q1 FY2024, three months to 2024-09-30−$0.54 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-11-14, accession 0001193125-25-281539.Report this figurenot reported(0.15)Basic EPS, Q1 FY2025, three months to 2025-03-31−$0.15 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-05-15, accession 0001193125-26-227245.Report this figure(0.21)Basic EPS, Q2 FY2025, three months to 2025-06-30−$0.21 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-08-14, accession 0001193125-26-350451.Report this figure(0.14)Basic EPS, Q3 FY2025, three months to 2025-09-30−$0.14 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-11-14, accession 0001193125-25-281539.Report this figurenot reported(0.13)Basic EPS, Q1 FY2026, three months to 2026-03-31−$0.13 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-05-15, accession 0001193125-26-227245.Report this figure(0.14)Basic EPS, Q2 FY2026, three months to 2026-06-30−$0.14 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-08-14, accession 0001193125-26-350451.Report this figure

Balance sheet

Cash and equivalents$996.0k, Q2 FY2026
Long-term debt$3.6m, Q2 FY2026
Shareholders' equity$18.5m, Q2 FY2026
TuHURA Biosciences, Inc., balance sheet, quarterly
Line itemUnitQ1 FY20232023-09-30Q2 FY20232023-12-31Q3 FY20242024-03-31FY20242024-06-30Q1 FY20242024-09-30FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Cash and equivalents$m0.2Cash and equivalents, Q1 FY2023, at 2023-09-30$216.0k. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2023-11-13, accession 0000950170-23-062915.Report this figure3.7Cash and equivalents, Q2 FY2023, at 2023-12-31$3.7m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-K filed 2025-03-31, accession 0000950170-25-047921.Report this figure6.4Cash and equivalents, Q3 FY2024, at 2024-03-31$6.4m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2024-05-14, accession 0000950170-24-059694.Report this figure4.9Cash and equivalents, FY2024, at 2024-06-30$4.9m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2024-11-14, accession 0000950170-24-127199.Report this figure3.0Cash and equivalents, Q1 FY2024, at 2024-09-30$3.0m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2024-11-14, accession 0000950170-24-127199.Report this figure12.7Cash and equivalents, FY2024, at 2024-12-31$12.7m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-K filed 2026-03-31, accession 0001193125-26-134950.Report this figure6.2Cash and equivalents, Q1 FY2025, at 2025-03-31$6.2m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-05-15, accession 0000950170-25-072745.Report this figure8.5Cash and equivalents, Q2 FY2025, at 2025-06-30$8.5m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-08-14, accession 0000950170-25-108972.Report this figure2.7Cash and equivalents, Q3 FY2025, at 2025-09-30$2.7m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-11-14, accession 0001193125-25-281539.Report this figure3.6Cash and equivalents, FY2025, at 2025-12-31$3.6m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-08-14, accession 0001193125-26-350451.Report this figure6.3Cash and equivalents, Q1 FY2026, at 2026-03-31$6.3m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-05-15, accession 0001193125-26-227245.Report this figure1.0Cash and equivalents, Q2 FY2026, at 2026-06-30$996.0k. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-08-14, accession 0001193125-26-350451.Report this figure
Current assets$m0.8Current assets, Q1 FY2023, at 2023-09-30$783.0k. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2023-11-13, accession 0000950170-23-062915.Report this figure4.2Current assets, Q2 FY2023, at 2023-12-31$4.2m. XBRL concept us-gaap:AssetsCurrent. 10-K filed 2025-03-31, accession 0000950170-25-047921.Report this figure6.8Current assets, Q3 FY2024, at 2024-03-31$6.8m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-05-14, accession 0000950170-24-059694.Report this figure5.5Current assets, FY2024, at 2024-06-30$5.5m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-11-14, accession 0000950170-24-127199.Report this figure3.5Current assets, Q1 FY2024, at 2024-09-30$3.5m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-11-14, accession 0000950170-24-127199.Report this figure19.6Current assets, FY2024, at 2024-12-31$19.6m. XBRL concept us-gaap:AssetsCurrent. 10-K filed 2026-03-31, accession 0001193125-26-134950.Report this figure14.3Current assets, Q1 FY2025, at 2025-03-31$14.3m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-05-15, accession 0000950170-25-072745.Report this figure12.5Current assets, Q2 FY2025, at 2025-06-30$12.5m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-08-14, accession 0000950170-25-108972.Report this figure3.5Current assets, Q3 FY2025, at 2025-09-30$3.5m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-11-14, accession 0001193125-25-281539.Report this figure4.6Current assets, FY2025, at 2025-12-31$4.6m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-08-14, accession 0001193125-26-350451.Report this figure7.0Current assets, Q1 FY2026, at 2026-03-31$7.0m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-05-15, accession 0001193125-26-227245.Report this figure1.7Current assets, Q2 FY2026, at 2026-06-30$1.7m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-08-14, accession 0001193125-26-350451.Report this figure
Total assets$m1.5Total assets, Q1 FY2023, at 2023-09-30$1.5m. XBRL concept us-gaap:Assets. 10-Q filed 2023-11-13, accession 0000950170-23-062915.Report this figure4.4Total assets, Q2 FY2023, at 2023-12-31$4.4m. XBRL concept us-gaap:Assets. 10-K filed 2025-03-31, accession 0000950170-25-047921.Report this figure7.4Total assets, Q3 FY2024, at 2024-03-31$7.4m. XBRL concept us-gaap:Assets. 10-Q filed 2024-05-14, accession 0000950170-24-059694.Report this figure6.2Total assets, FY2024, at 2024-06-30$6.2m. XBRL concept us-gaap:Assets. 10-Q filed 2024-11-14, accession 0000950170-24-127199.Report this figure4.1Total assets, Q1 FY2024, at 2024-09-30$4.1m. XBRL concept us-gaap:Assets. 10-Q filed 2024-11-14, accession 0000950170-24-127199.Report this figure20.0Total assets, FY2024, at 2024-12-31$20.0m. XBRL concept us-gaap:Assets. 10-K filed 2026-03-31, accession 0001193125-26-134950.Report this figure14.6Total assets, Q1 FY2025, at 2025-03-31$14.6m. XBRL concept us-gaap:Assets. 10-Q filed 2025-05-15, accession 0000950170-25-072745.Report this figure34.6Total assets, Q2 FY2025, at 2025-06-30$34.6m. XBRL concept us-gaap:Assets. 10-Q filed 2025-08-14, accession 0000950170-25-108972.Report this figure25.7Total assets, Q3 FY2025, at 2025-09-30$25.7m. XBRL concept us-gaap:Assets. 10-Q filed 2025-11-14, accession 0001193125-25-281539.Report this figure27.4Total assets, FY2025, at 2025-12-31$27.4m. XBRL concept us-gaap:Assets. 10-Q filed 2026-08-14, accession 0001193125-26-350451.Report this figure29.7Total assets, Q1 FY2026, at 2026-03-31$29.7m. XBRL concept us-gaap:Assets. 10-Q filed 2026-05-15, accession 0001193125-26-227245.Report this figure31.7Total assets, Q2 FY2026, at 2026-06-30$31.7m. XBRL concept us-gaap:Assets. 10-Q filed 2026-08-14, accession 0001193125-26-350451.Report this figure
Current liabilities$m3.3Current liabilities, Q1 FY2023, at 2023-09-30$3.3m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2023-11-13, accession 0000950170-23-062915.Report this figure3.6Current liabilities, Q2 FY2023, at 2023-12-31$3.6m. XBRL concept us-gaap:LiabilitiesCurrent. 10-K filed 2025-03-31, accession 0000950170-25-047921.Report this figure1.3Current liabilities, Q3 FY2024, at 2024-03-31$1.3m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-05-14, accession 0000950170-24-059694.Report this figure2.3Current liabilities, FY2024, at 2024-06-30$2.3m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-11-14, accession 0000950170-24-127199.Report this figure2.3Current liabilities, Q1 FY2024, at 2024-09-30$2.3m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-11-14, accession 0000950170-24-127199.Report this figure5.3Current liabilities, FY2024, at 2024-12-31$5.3m. XBRL concept us-gaap:LiabilitiesCurrent. 10-K filed 2026-03-31, accession 0001193125-26-134950.Report this figure4.8Current liabilities, Q1 FY2025, at 2025-03-31$4.8m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-05-15, accession 0000950170-25-072745.Report this figure15.2Current liabilities, Q2 FY2025, at 2025-06-30$15.2m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-08-14, accession 0000950170-25-108972.Report this figure8.8Current liabilities, Q3 FY2025, at 2025-09-30$8.8m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-11-14, accession 0001193125-25-281539.Report this figure5.9Current liabilities, FY2025, at 2025-12-31$5.9m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-08-14, accession 0001193125-26-350451.Report this figure6.1Current liabilities, Q1 FY2026, at 2026-03-31$6.1m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-05-15, accession 0001193125-26-227245.Report this figure9.3Current liabilities, Q2 FY2026, at 2026-06-30$9.3m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-08-14, accession 0001193125-26-350451.Report this figure
Total liabilities$m3.5Total liabilities, Q1 FY2023, at 2023-09-30$3.5m. XBRL concept us-gaap:Liabilities. 10-Q filed 2023-11-13, accession 0000950170-23-062915.Report this figure5.9Total liabilities, Q2 FY2023, at 2023-12-31$5.9m. XBRL concept us-gaap:Liabilities. 10-K filed 2025-03-31, accession 0000950170-25-047921.Report this figure1.5Total liabilities, Q3 FY2024, at 2024-03-31$1.5m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-05-14, accession 0000950170-24-059694.Report this figure2.4Total liabilities, FY2024, at 2024-06-30$2.4m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-11-14, accession 0000950170-24-127199.Report this figure2.4Total liabilities, Q1 FY2024, at 2024-09-30$2.4m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-11-14, accession 0000950170-24-127199.Report this figure5.4Total liabilities, FY2024, at 2024-12-31$5.4m. XBRL concept us-gaap:Liabilities. 10-K filed 2026-03-31, accession 0001193125-26-134950.Report this figure4.8Total liabilities, Q1 FY2025, at 2025-03-31$4.8m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-05-15, accession 0000950170-25-072745.Report this figure15.2Total liabilities, Q2 FY2025, at 2025-06-30$15.2m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-08-14, accession 0000950170-25-108972.Report this figure8.9Total liabilities, Q3 FY2025, at 2025-09-30$8.9m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-11-14, accession 0001193125-25-281539.Report this figure6.4Total liabilities, FY2025, at 2025-12-31$6.4m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-08-14, accession 0001193125-26-350451.Report this figure6.5Total liabilities, Q1 FY2026, at 2026-03-31$6.5m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-05-15, accession 0001193125-26-227245.Report this figure13.2Total liabilities, Q2 FY2026, at 2026-06-30$13.2m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-08-14, accession 0001193125-26-350451.Report this figure
Long-term debt$mnot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reported3.6Long-term debt, Q2 FY2026, at 2026-06-30$3.6m. XBRL concept us-gaap:LongTermDebt. 10-Q filed 2026-08-14, accession 0001193125-26-350451.Report this figure
Current portion of debt$mnot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reported
Shareholders' equity$m(2.0)Shareholders' equity, Q1 FY2023, at 2023-09-30−$2.0m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2024-11-14, accession 0000950170-24-127199.Report this figure(1.6)Shareholders' equity, Q2 FY2023, at 2023-12-31−$1.6m. XBRL concept us-gaap:StockholdersEquity. 10-K filed 2026-03-31, accession 0001193125-26-134950.Report this figure(6.1)Shareholders' equity, Q3 FY2024, at 2024-03-31−$6.1m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-14, accession 0001193125-25-281539.Report this figure(7.0)Shareholders' equity, FY2024, at 2024-06-30−$7.0m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-14, accession 0001193125-25-281539.Report this figure(2.8)Shareholders' equity, Q1 FY2024, at 2024-09-30−$2.8m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-14, accession 0001193125-25-281539.Report this figure14.6Shareholders' equity, FY2024, at 2024-12-31$14.6m. XBRL concept us-gaap:StockholdersEquity. 10-K filed 2026-03-31, accession 0001193125-26-134950.Report this figure9.9Shareholders' equity, Q1 FY2025, at 2025-03-31$9.9m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-14, accession 0001193125-26-350451.Report this figure19.4Shareholders' equity, Q2 FY2025, at 2025-06-30$19.4m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-14, accession 0001193125-26-350451.Report this figure16.8Shareholders' equity, Q3 FY2025, at 2025-09-30$16.8m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-14, accession 0001193125-25-281539.Report this figure20.9Shareholders' equity, FY2025, at 2025-12-31$20.9m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-14, accession 0001193125-26-350451.Report this figure23.2Shareholders' equity, Q1 FY2026, at 2026-03-31$23.2m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-14, accession 0001193125-26-350451.Report this figure18.5Shareholders' equity, Q2 FY2026, at 2026-06-30$18.5m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-14, accession 0001193125-26-350451.Report this figure

Cash flow

Operating cash flow−$8.6m, Q2 FY2026
Capital expenditure$137.0k, Q2 FY2026
TuHURA Biosciences, Inc., cash flow, quarterly
Line itemUnitQ1 FY20232023-09-30Q2 FY20232023-12-31Q3 FY20242024-03-31Q4 FY20242024-06-30Q1 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Operating cash flow$m(1.3)Operating cash flow, Q1 FY2023, three months to 2023-09-30−$1.3m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2024-11-14, accession 0000950170-24-127199.Report this figure(2.1)Operating cash flow, Q2 FY2023, three months to 2023-12-31−$2.1m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2024-02-14, accession 0000950170-24-015204. Derived: 6-month figure less the 3-month figure.Report this figure(3.8)Operating cash flow, Q3 FY2024, three months to 2024-03-31−$3.8m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-05-15, accession 0000950170-25-072745.Report this figure(1.4)Operating cash flow, Q4 FY2024, three months to 2024-06-30−$1.4m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2024-10-07, accession 0000950170-24-113321. Derived: 12-month figure less the 9-month figure.Report this figure(1.9)Operating cash flow, Q1 FY2024, three months to 2024-09-30−$1.9m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2024-11-14, accession 0000950170-24-127199.Report this figure(2.6)Operating cash flow, Q4 FY2024, three months to 2024-12-31−$2.6m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-03-31, accession 0001193125-26-134950. Derived: 12-month figure less the 9-month figure.Report this figure(4.7)Operating cash flow, Q1 FY2025, three months to 2025-03-31−$4.7m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-15, accession 0001193125-26-227245.Report this figure(6.2)Operating cash flow, Q2 FY2025, three months to 2025-06-30−$6.2m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-14, accession 0001193125-26-350451. Derived: 6-month figure less the 3-month figure.Report this figure(11.1)Operating cash flow, Q3 FY2025, three months to 2025-09-30−$11.1m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-14, accession 0001193125-25-281539. Derived: 9-month figure less the 6-month figure.Report this figure(5.6)Operating cash flow, Q4 FY2025, three months to 2025-12-31−$5.6m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-03-31, accession 0001193125-26-134950. Derived: 12-month figure less the 9-month figure.Report this figure(4.4)Operating cash flow, Q1 FY2026, three months to 2026-03-31−$4.4m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-15, accession 0001193125-26-227245.Report this figure(8.6)Operating cash flow, Q2 FY2026, three months to 2026-06-30−$8.6m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-14, accession 0001193125-26-350451. Derived: 6-month figure less the 3-month figure.Report this figure
Capital expenditure$mnot reportednot reportednot reportednot reported0.0Capital expenditure, Q3 FY2024, three months to 2024-09-30$0. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-11-14, accession 0001193125-25-281539. Derived: 9-month figure less the 6-month figure.Report this figure0.0Capital expenditure, Q4 FY2024, three months to 2024-12-31$21.4k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-03-31, accession 0001193125-26-134950. Derived: 12-month figure less the 9-month figure.Report this figure0.0Capital expenditure, Q1 FY2025, three months to 2025-03-31$42.7k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-05-15, accession 0001193125-26-227245.Report this figure0.0Capital expenditure, Q2 FY2025, three months to 2025-06-30$5.6k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-14, accession 0001193125-26-350451. Derived: 6-month figure less the 3-month figure.Report this figure0.0Capital expenditure, Q3 FY2025, three months to 2025-09-30$0. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-11-14, accession 0001193125-25-281539. Derived: 9-month figure less the 6-month figure.Report this figure0.0Capital expenditure, Q4 FY2025, three months to 2025-12-31$27.9k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-03-31, accession 0001193125-26-134950. Derived: 12-month figure less the 9-month figure.Report this figure0.0Capital expenditure, Q1 FY2026, three months to 2026-03-31$48.8k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-05-15, accession 0001193125-26-227245.Report this figure0.1Capital expenditure, Q2 FY2026, three months to 2026-06-30$137.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-14, accession 0001193125-26-350451. Derived: 6-month figure less the 3-month figure.Report this figure

Shares

Diluted shares (weighted)63.96m, Q2 FY2026
TuHURA Biosciences, Inc., shares, quarterly
Line itemUnitQ1 FY20142014-03-31Q1 FY20152014-09-30Q2 FY20152014-12-31Q3 FY20152015-03-31Q3 FY20242024-03-31Q4 FY20242024-06-30Q1 FY20242024-09-30Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q1 FY20262026-03-31Q2 FY20262026-06-30
Diluted shares (weighted)m shares31.7Diluted shares (weighted), Q1 FY2014, three months to 2014-03-3131,659,791 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2015-05-15, accession 0001013762-15-000525.Report this figure36.5Diluted shares (weighted), Q1 FY2015, three months to 2014-09-3036,451,014 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2014-11-07, accession 0001013762-14-001293.Report this figure37.8Diluted shares (weighted), Q2 FY2015, three months to 2014-12-3137,798,183 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2015-02-12, accession 0001013762-15-000152.Report this figure39.0Diluted shares (weighted), Q3 FY2015, three months to 2015-03-3138,976,827 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2015-05-15, accession 0001013762-15-000525.Report this figure12.2Diluted shares (weighted), Q3 FY2024, three months to 2024-03-3112,173,732 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-05-15, accession 0000950170-25-072745.Report this figure12.2Diluted shares (weighted), Q4 FY2024, three months to 2024-06-3012,178,522 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-08-14, accession 0000950170-25-108972.Report this figure12.2Diluted shares (weighted), Q1 FY2024, three months to 2024-09-3012,178,522 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-11-14, accession 0001193125-25-281539.Report this figure43.4Diluted shares (weighted), Q1 FY2025, three months to 2025-03-3143,404,947 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-05-15, accession 0001193125-26-227245.Report this figure44.6Diluted shares (weighted), Q2 FY2025, three months to 2025-06-3044,555,095 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-08-14, accession 0001193125-26-350451.Report this figure50.7Diluted shares (weighted), Q3 FY2025, three months to 2025-09-3050,666,430 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-11-14, accession 0001193125-25-281539.Report this figure60.0Diluted shares (weighted), Q1 FY2026, three months to 2026-03-3160,010,237 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-05-15, accession 0001193125-26-227245.Report this figure64.0Diluted shares (weighted), Q2 FY2026, three months to 2026-06-3063,963,513 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-08-14, accession 0001193125-26-350451.Report this figure

Shares outstanding: 63.73mShares outstanding, period not labelled, at 2026-08-1163,726,617 shares. XBRL concept dei:EntityCommonStockSharesOutstanding. 10-Q filed 2026-08-14, accession 0001193125-26-350451.Report this figure at Aug 11, 2026, from the cover of the 10-Q filed Aug 14, 2026.

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:41 ET. Listed shows no prices and gives no investment advice.